2026 POSTER PRESENTATIONS

Poster Awards will be announced Wednesday, during the 9:35 - 10:30am Coffee Break and Thursday, during the 1:30 - 2:10pm Refreshment Break.

P001: Discovery of Potent and Selective, VHL-Based STAT6 PROTACs for Oral Treatment of Type II Inflammatory Diseases, Presented by Jordi B., Almirall, S.A.

P002: The Development and Application of DNA-Encoded Cyclic Peptide Libraries, Presented by Xuan W., AlphaMa Biotechnology

P003: From Binding to Degradation: Multiscale Insight of PROTAC Mediated Protein Targets, Presented by Edward P., Aragen Life Sciences

P004: Machine Learning–Guided De Novo Design of a Proprietary PPI Modulator Library, Presented by Iolanda M., Axxam SpA

P005: A High-Throughput Screening and Triage Platform for Identifying PPI Disruptors in Cancer, Presented by Mariantonietta R., Axxam SpA

P006: High-Throughput Peptide Screening for Radioligands by DNA Encoded Libraries, Presented by Fengping X., BioDuro

P007: Label-Free Characterization of Binding Kinetics of Anti-HER1, Anti-HER2 and Anti-HER3 Therapeutic Antibodies in Whole Single Cells Using Surface Plasmon Resonance Microscopy (SPRM), Presented by Akemi U., Biosensing Instrument

P008: Exploring Novel Cancer Therapeutics with Generative Design at OICR, Presented by Kevin C., BIOVIA by Dassault Systèmes

P009: Unraveling PROTAC Mechanisms: from DEL Screening to Cellular Degradation Through Biophysical Profiling, Presented by Matthew P., Bruker

P010: Development of a First-in-Class MCL-1 Degrader: A Cardiosafe Therapeutic Strategy for AML Treatment, Presented by Andrzej T., Captor Therapeutics S.A.

P011: LiLis: Harnessing New E3 Ligases for Targeted Protein Degradation Platform, Presented by Bartosz W., Captor Therapeutics S.A.

P012: HT-SPR Screening and Kinetic Characterization of Small-Molecule Binders Using Carterra Vega™ and Comparison with AI Binding Predictions, Presented by Bo P., Carterra, Inc.

P013: Massively Parallel SPR-Based Fragment Screening of Kinase Arrays, Presented by Bo P., Carterra, Inc.

P014: Increasing DNA Encoded Library Screening Resolution Using HT-SPR, Presented by Christopher S., Carterra, Inc.

P015: Validation and Characterization of Anti-Citrulline Antibodies and Citrullinated Proteins, Presented by Kendall M., Cayman Chemical Company

P016: MICRO-TAG® Cell Target Engagement Redefines GPCR Drug Discovery with Functional Relevance, Presented by Ivan B., CellarisBio

P017: A Cellular Target Engagement Atlas of 100+ Drug Targets Validated by MICRO-TAG Platform, Presented by Elmar N., CellarisBio

P018: Cellular DNA-Encoded Library (DEL) Screening Coupled with MICRO-TAG® Real-Time Cellular Target Engagement Enables Discovery of Novel Therapeutics, Presented by Elmar N., CellarisBio

P019: AI-Guided Discovery of Novel a7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulators Using Iterative Generative Design, Presented by Tatiana P., Chapman University

P020: In Vitro and in Vivo Study of C2LP-ADC & CLP2-ADC Targeting Human Breast and Gastric Cancer, Presented by Bing L., ChemPartner Corporation

P021: Discovery, Design, and Delivery of New Inhibitors for NSP13 Through High-Performance Chemspace Platform, Presented by Kateryna H., Chemspace LLC

P022: Freedom Space 5.0: Enabling Diversity and Synthetic Feasibility in Billion-Scale Chemical Space, Presented by Olga T., Chemspace LLC

P023: CMX-001: A First-in-Class, Irreversible FAP-Targeting Radiotherapeutic with Human Proof-of-Concept Enabled by the ChomiX Chemoproteomic Platform, Presented by Nan C., ChomiX Biotech Co., Ltd.

P024: Hyaline: Geometric Deep Learning for Accurate Prediction of G Protein-Coupled Receptor Activation States from Structure, Presented by Harry K., Columbia University

P025: Targeting the NLRP3 Inflammasome: Advancing Small Molecule Inhibitors for Inflammatory Disease Treatment, Presented by Adam D., Concept Life Sciences

P026: An active Learning FEP Workflow to Identify the Most Promising Molecules to Make and Test, Presented by Kien N., Cresset

P027: Discovering Ligands for Novel Pockets and “Hard-to-Drug” Targets with Live-Cell Data, Presented by Mohammad E., Dalriada Drug Discovery, Inc.

P028: SpiroQuest: Macrocycle Library, Novel Macrocycle Design and Virtual Library, Presented by Thomas F., Dalriada Drug Discovery, Inc.

P029: Advancing Drug Discovery with DEL-Pilot and Integrated DEL-Source Workflows, Presented by Svetlana B., DEL Source

P030: Accelerating Covalent Drug Discovery Through Computational Design and Medicinal Chemistry with CovScan, Presented by Ghotas E., DEL Source

P031: Characterization of the Role of GALE in Airway Mucin Biosynthesis, Presented by Sai Kwan K., Duke University

P032: Accelerating Molecular Glue Discovery Through Novel Chemical Space and ASMS Screening, Presented by Hugues L., Edelris

P033: Unified Scientific Workflows with iTraX™: Connecting Teams, Data and Decisions Across Drug Discovery, Presented by Kate D., Elixir Software Ltd.

P034: Discovery of Novel BRD4-Targeting PROTAC Degraders Using Enamine’s E3 Ligase–Linker Conjugate Platform, Presented by Dave H., Enamine Ltd

P035: Integrated High-Throughput Biochemical Binding and Cell-Based Targeted Protein Degradation Assay Platforms for STAT Degraders, Presented by Alexander C., Eurofins Discovery

P036: Characterization of Next-Generation Obesity Therapeutics Using Preclinical and Translational Models, Presented by Jennifer D., Eurofins Discovery

P037: Discovery of WEE1 Degraders: Integrating Macrocyclic PROTAC Design and High-Throughput Molecular Glue Screening, Presented by Olivier M., Eurofins Discovery

P038: Expediting GPCR Drug Discovery: Dual Strategy Combining Spectral Shift Screening and Coarse-Grained Molecular Dynamics for A[2A]R, Presented by Vanessa P., Eurofins Discovery

P039: Comprehensive Analysis of Clinically Discontinued Compounds Using and In Vitro Secondary Pharmacology Panel to Predict Safety Liabilities, Presented by Danielle S., Eurofins Discovery

P040: Bayesian Optimization-Driven Compound Selection for Direct-to-Biology Approaches in Drug Discovery, Presented by Elizabeth F., Evotec

P041: Small Molecule Interactions with Membrane Proteins Using Flow Induced Dispersion Analysis, Presented by Mark K., Fidabio

P042: Discovery of Novel E3 Ligase Ligands for Targeted Protein Degraders with a Phenotypic-First Approach to Expand Degrader Landscape, Presented by Shinya Y., FIMECS, Inc.

P043: CyclicChamp: Heuristic Energy-Based Cyclic Peptide Design, Presented by Qiyao Z., Flatiron Institute

P044: Assessing Cellular Target Engagement with MICRO-TAG®: ARID1B as an “Undruggable" Case Study, Presented by Huarui C., Foghorn Therapeutics

P045: Structure-Based Graph Neural Network for Zero-Shot Drug Similarity Prediction, Presented by Pranjal G., Georgia Institute of Technology

P046: ADME at Scale: High-Throughput Data Generation to Power AI-Enabled Drug Discovery, Presented by Abraham W., Ginkgo Bioworks

P047: Ligand-Based CRBN Molecular Glue Library: Design, Screening, and Application in Hit Discovery, Presented by Hongbo Z., HitChem

P048: How Med Chem MET DMPK to Discover the First FDA Approved Selective c-Met Inhibitor Capmatinib, Presented by David B., Incyte Corporation

P049: Beyond the Leaderboard: How Probabilistic Dose Projection Changes Compound Prioritization, Presented by Nic P., Inductive Bio

P050: Electrophoretic Selections with DNA-Encoded Libraries Provide Training Sets with Massively High-Throughput Affinity Measurements, Presented by Gavin H., insitro

P051: Synthesis of Bivalent Programmed DNA-Encoded Libraries: Exploiting Avidity to Capture the Low-Affinity Gradient for Predictive Binding Models, Presented by Divya K., insitro

P052: Rapid Design of Quantitative Adaptive Libraries (QALs) with an ML Enabled Web Application, Presented by Nate S., insitro

P053: Programmed DNA-Encoded Library Synthesis: Overcoming Combinatorial Constraints to Enable Surgical Construction of Active Learning Training Sets, Presented by Joshua T., insitro

P054: Quantitative Adapted Libraries: Making ML-Driven Lead Optimization a Reality, Presented by Eray W., insitro

P055: Electrophile-First Approach Enables Rapid Identification of ATP-Competitive Inhibitors of Werner Helicas, Presented by Christian M., IRBM S.p.A.

P056: ATLAS Breaks Data Scaling Barriers for Machine Learning via High-Throughput Synthesis and Screening, Presented by Neri A., Kimia Therapeutics

P057: Structural Diversity-Aware ADMET Data Curation and Validation for Federated Learning, Presented by Nayoung C., K-MEDI hub, Daegu-Gyeongbuk Medical Innovation Foundation

P058: In Silico-Driven Discovery of Novel Senotherapeutic Leads for Managing Metabolic Disorders, Presented by Jee-Young L., K-MEDI hub, Daegu-Gyeongbuk Medical Innovation Foundation

P059: Designing Stable Isotope-Labelled Internal Standards that Behave Like the Analyte in LC–MS Analysis, Presented by Chris M., LGC Standards USA

P060: Novel Fragment Libraries for Drug Discovery, Presented by George B., Life Chemicals, Inc.

P061: Screening Compound Libraries for HTS and Lead Discovery Projects, Presented by George B., Life Chemicals, Inc.

P062: LifeCheMyriads: Billions of Synthesis-Ready Molecules for Fast, Smart Drug Discovery, Presented by Vasily P., Life Chemicals, Inc.

P063: Integrating Machine Learning and Automation to Advance Retrosynthesis Planning and Custom Chemical Synthesis, Presented by Tamsin M., Mansley Scientific

P064: Patent Analysis -> Scaffold Hopping -> Improved ADMET Properties, Presented by Lauren R., MedChemica Ltd.

P065: Predicted Properties in Fragment-to-Lead Design, Presented by Jacqueline H., Merck & Co., Inc.

P066: Covalent Inhibitors for Treatment of Schizophrenia, Presented by Samantha B., Midwestern University

P067: Modulating m6A Using FTO Inhibitors for Treatment of Neurological Disease States, Presented by Mark O., Midwestern University

P068: Covalent Drug Discovery for Inhibition of Mitoptosis, Presented by Margaret O., Anthem Preparatory Academy

P069: 10x Higher Hit Rates at 3–10x Lower Costs: Accelerating Ligand Discovery with ML-Guided Synthesis and Screening, Presented by Piotr B., Molecule.one

P070: Selection of Functionalizable Ro3 Fragments from a 6M Compound Library to Support Fragment-Based Drug Discovery, Presented by Andrea A., MolPort

P071: Identifying Small Molecules that Modulate Hypoxia-Inducible Factor Nuclear Translocation, Presented by Estefania MM., National Institutes of Health, National Center for Advancing Translational Sciences

P072: Development of TRAP1 Agonist 1685 to Modulate Mitochondrial-Lysosomal Crosstalk, Presented by Ananya M., National Institutes of Health, National Center for Advancing Translational Sciences

P073: Molecular Determinants of CB1 Receptor Binding and Function in the Alkyl Pyrazoline-Based Urea and Thiourea Series, Presented by Subhradeep D., National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism

P074: Discovery and Validation of > 150 Novel CRBN Neosubstrates by High-Throughput Deep Proteomic Screening of 960 Molecular Glue Degrader Drugs, Presented by Patrick Z., NEOsphere Biotechnologies GmbH

P075: Comprehensive Biophysical Characterization of PROTAC Molecules Using Orthogonal Techniques, Presented by Laurent S., Novalix

P076: Macrocycles as Novel PI4KIIIb Inhibitors to Tackle Human Rhinoviruses Infections, Presented by Laurent S., Novalix

P077: Direct-to-Biology for Accelerated Drug Discovery, Presented by Robert F., Nuvisan ICB GmbH

P078: Accelerating the Next Generation of Induced Proximity Therapeutics: Novel Assays for RiboTAC Drug Design and RNA-Binding Molecules, Presented by Catherine S., o2h Discovery

P079: Closing the “Make” Gap in Early Drug Discovery: Automated On-Demand Synthesis from a 3.4 Billion Compound Library, Presented by Daniil B. & Andrei T., onepot.ai

P080: ROCS X: An AI-Enabled 3D Search Method for Robust, Rapid Virtual Screening of Trillions, Presented by Kalistyn L., OpenEye, Cadence Molecular Sciences

P081: Integrating Degradation, Engagement, and Selectivity: CETSA® as a Framework for Degrader Validation, Presented by Agata H., Pelago Bioscience

P082: mRNA Display - Revolutionizing Drug Discovery, Presented by Yongjin G., PeptiFinder Biotech, Inc.

P083: Next-Generation New Modality R&D and Manufacturing Enhanced by Innovations in Green, Low-Carbon, and Sustainable Technologies, Presented by Zhenzhen D., PharmaBlock

P084: Chemotype Discovery in Trillion Sized Chemical Spaces Using 3D Hydrophobicity Maps, Presented by Matthew M., Pharmacelera

P085: Encoded Display of Chemical Libraries on Nanoparticles for Protein Ligand Discovery, Presented by Jaesub K., Pohang University of Science and Technology (POSTECH)

P086: Highly Ordered Clustering of TNFa and BAFF Ligand-Receptor-Intracellular Adaptor Complexes on a Lipid Membrane, Presented by Ji Won K., Pohang University of Science and Technology (POSTECH)

P087: In Situ Click Chemistry Screen of an On-Nanoparticle DNA-Encoded Library for the Development of Selective and Potent Peptoid Ligands, Presented by Dong Min S., Pohang University of Science and Technology (POSTECH)

P088: Delivering Impermeable Probes and Tracers for Intracellular Measurement of Protein Degradation, Target Engagement, and Screening in Live Cells, Presented by Karen G., Portal Biotechnologies

P089: Enabling Live Cell Assays with a Silicon Membrane-Based Platform for Mechanical Delivery to Accelerate Early Drug Discovery, Presented by Zulfiqar M., Portal Biotechnologies

P090: Innovative Bioluminescence Assays for Monitoring GPCR Dynamics: Advancing Therapeutic Strategies for Metabolic Disease, Presented by Steven E., Promega Corporation

P091: De-Risking CRBN-Recruiting Degraders: Characterizing Neosubstrate Degradation Specificity and Selectivity, Presented by Alissa K., Promega Corporation

P092: BRETSA: An Ultra-Sensitive, Broadly-Applicable BRET Method to Measure Target Engagement Through Protein Denaturation in Live Cells, Presented by James V., Promega Corporation

P093: Real-Time Monitoring of Targeted Protein Degradation in Living Cells: Enabling Live-Cell Kinetic Analysis at Every Step, Presented by Tian Y., Promega Corporation

P094: A Quantum-Enhanced Framework for Modeling Protein–Ligand Binding Energies in Drug Discovery, Presented by Jaehong S., Qunova Computing, Inc.

P095: Repurposing Kinase Inhibitors to Target Rare Cancers, Presented by Haiching M., Reaction Biology

P096: Massive MD Simulations on Fugaku Reveal the LIMS-W Mechanism: A Novel Structural Basis for Designing Amyloid Disaggregators, Presented by Hideyuki M., RIKEN

P097: Discovery of Novel GPR34 Chemical Probes Through Virtual Screening and In-Vitro Evaluation, Presented by Robert D., Saint Louis University

P098: Scaling Binding Affinity Prediction with Physics-Augmented AI and Free Energy Calculations: Application to E3 Ligase Modulators, Presented by Ly L., SandboxAQ

P099: Pharmacological Profiling of GPCRs: A Hybrid Machine Learning and Physics-Based Framework for Mechanism of Action Prediction, Presented by Rae Q., SandboxAQ

P100: Discovery and Development of Novel Autophagy Inhibiting ATG13 Degrading Compounds, Presented by Patrick H., Sanford Burnham Prebys

P101: Modeling of Bifunctional Degrader Ternary Complexes and Potency Optimization Using the Schrödinger Platform, Presented by Anatoly R., Schrödinger, Inc.

P102: Elevating Speed and Sensitivity: Integration of Acoustic Ejection with the Next Generation QTOF Mass Spectrometer, Presented by Rahul B., SCIEX

P103: Chemical Proteomics Reveals Orthosteric Bias in Protein-Ligand Co-Folding Models, Presented by Raymond B., Scripps Research Institute

P104: Binder2030: A Standardized Quantitative Binding Resource for Membrane Protein Drug Discovery, Presented by Tiffany N., SEEDSUPPLY, Inc.

P105: A Deubiquitin-Dependent Stability Regulator Controls a Stress-Adaptation Factor via Direct Protein–Protein Interaction in PDAC, Presented by Jinuk J., Seoul National University Hospital

P106: Structure-Guided Profiling of a Chaperone-Mediated Protein–Protein Interaction Associated with Immune-Regulatory Features in Pancreatic Cancer, Presented by Hyeon Woong K., Seoul National University Hospital

P107: Deubiquitinase-Dependent Stabilization of SMAD Signaling Drives Chemoresistance in KRAS-Mutant Pancreatic Cancer, Presented by Hyo Jung K., Seoul National University Hospital

P108: Multimodal Machine Learning for GPCR Hit Identification: Integrating Million-Scale DEL and HTS Datasets for Billion-Compound Virtual Screening, Presented by Helen V., Septerna, Inc.

P109: Novel Descriptors and Models for More Accurate ADME and PK Predictions of Beyond Rule of Five Molecules, Presented by Jeremy J., Simulations Plus

P110: LCK-Targeting Molecular Glues Overcome Resistance to Inhibitor-Based Therapy in T-Cell Acute Lymphoblastic Leukemia, Presented by Marisa A., St. Jude Children's Research Hospital

P111: A Robust Pipeline for De Novo Macrocyclic Peptide Discovery Using Deep Learning and High-Throughput Screening, Presented by Guanhua H., Stanford University

P112: A Structural Platform for Molecular Glues and PROTACs Discovery: SPR Fragment Screening and Crystallography Hit Validation with CRBN[midi], Presented by René C., Sygnature Discovery

P113: LRRK2 Degrader Discovery: A High Throughput Direct-to-Biology Screening Platform, Presented by Allan J., Sygnature Discovery

P114: Through Hit Synergy and Beyond! Integrating Hit Finding and Direct-to-Biology to Shorten Time to Development Candidate, Presented by Allan J., Sygnature Discovery

P115: Why Early Process Chemistry Matters?, Presented by Romain L., Sygnature Discovery

P116: Generative AI and Machine Learning–Driven Design of Novel MAO-B Inhibitors for Parkinson’s Disease, Presented by Vincent S., Taylor University

P117: The Search for Molecular Glues and Non-Inhibitory E3 Ligands via On-Bead Ubiquitination Assay in OBOC DELs, Presented by Michal TR., UF Scripps Institute for Biomedical Innovation and Technology

P118: An Organometallic Chemistry Approach to Peptide Tricycles, Presented by Nima A., University of California, Los Angeles

P119: Structure-Based Virtual Screening Reveals Novel Anti-Coccidioides Compounds, Presented by Arianna D., University of California, Merced

P120: Targeted Degradation of Pin1 by Molecular Crowbars, Presented by Giulia A., University of California, Riverside

P121: Detection of Circulating Exosome-Associated EphA2 from Pancreatic Cancer Cells and Patient Serum Using Simple Western and ELISA, Presented by Sara A., University of California, Riverside

P122: Covalent Targeting of Histidine Residues, Presented by Emma A., University of California, Riverside

P123: His/Lys Covalent BAK Inhibitors as Neuroprotective Agents, Presented by Mirna H., University of California, Riverside

P124: In Silico Fragment-Based Mapping of N-Terminal Pockets in TCPTP to Guide Pharmacophore Design, Presented by Roxanna H., University of California, Riverside

P125: Histidine-Covalent Cyclic Aryl-Fluorosulfate Peptides Targeting KRAS Mutants, Presented by Anne Marie P., University of California, Riverside

P126: Novel Mcl-1 His and Lys Covalent Agents from a Fragment-Merging Approach, Presented by Daniele R., University of California, Riverside

P127: A Degron Decoy System Co-Opts Pathological Seeding to Enable Clearance of Multimeric Alpha-Synuclein, Presented by Gillian G., University of California, San Diego

P128: Transparent Acceleration of Structure-Based Virtual Screening with ChemSTEP, Presented by Katie H., University of California, San Francisco

P129: Million-Scale Macrocycle Docking for Drug Discovery, Presented by Divya K., University of California, San Francisco

P130: Real-Time NanoBRET Target Engagement Reveals Permeability-Activity Relationships in BET-Targeting Degraders, Presented by Alexander E., University of California, Santa Cruz

P131: The Search for Pharmacological Control over the Circadian Clock, Presented by McClain K., University of California, Santa Cruz

P132: Rational Design and Conformational Analysis of CuAAC-Derived Heptamers: Biasing Beyond-Rule-of-5 Macrocycles for Passive Membrane Permeability, Presented by Cristobal M., University of California, Santa Cruz

P133: High-Throughput Cyclic Peptide Screening Using DNA-Encoded Libraries, Presented by Janet T., University of California, Santa Cruz

P134: CRANBERRY: A Coarse-Grained RNA Model that Folds Tetraloops De Novo, Presented by Yiheng W., University of Chicago

P135: Subtyping Small-Molecule Binding Mode to Abelson Kinase Using Nanopore Tweezers: Resolution of Orthosteric, Allosteric, and Co-Binding Interactions, Presented by Joshua F., University of Massachusetts, Amherst

P136: DELs in Cells – Nuclear DNA-Binding Protein Screening, Presented by Leif L., Vipergen

P137: Targeting Transcription Factor FOSL1 as a Therapeutic Strategy for Head and Neck Squamous Cell Carcinoma, Presented by Sarita P., Virginia Commonwealth University

P138: Innovative Approaches to Peptide Drug Development: From Discovery to Commercial, Presented by Yinghong G., Viva Biotech

P139: Targeted In Vitro Pharmacology for GIPR/GLP-1R/GCGR in Weight Loss and Type 2 Diabetes Therapy, Presented by Fei D., WuXi AppTec, Inc.

P140: Biophysical Method and Platform Development for Rapid High Throughput Screening and Hit Validation, Presented by Ishrat J., WuXi AppTec, Inc.

P141: Unleashing the Power of Spectral Shift Technology for Ultra-High-Throughput Binding Assays, Presented by Michael R., WuXi AppTec, Inc.

P142: DNA-Encoded Libraries and Display Technologies Empower Early Discovery of Peptide Drugs and Peptide-Based Delivery Tools, Presented by Rhys T., WuXi AppTec, Inc.

P143: In Silico Mapping of Structural Anchors: Identifying Critical C-Beta and N-Me Sites in Cyclosporine A via Semi-Systematic Truncation, Presented by Satoshi O., Xeureka, Inc.

P144: Discovery of Picomolar-Selective RNA-Targeted Small Molecules via MatrixFOREST Using RNA Focused Chemical Library, Presented by Hiroki Y., xFOREST Therapeutics Co., Ltd.

P145: Agentic AI Toward Autonomous Discovery: VAST Chemical Libraries and Synthesis Enabled by Proprietary Data and Robotics, Presented by Greg P., XtalPi

P146: Prospective Discovery of Molecular Glue Degraders Using AI-Guided Chemical Space Design and Robotics-Controlled Automated Synthesis, Presented by Yang X., XtalPi

P147: Drugging Fungal Group I Introns Reveals a New Pathway for Antifungal Therapy, Presented by Jimin H., Yale University

P148: Discovery of Novel Bis-Arylamidines with Broad-Spectrum Activity Against Molds and Yeasts, Presented by Tao S., Yale University